LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | SNS-032 | 10 | uM | LJP6 | 1 | H13 | 72 | hr | 2543 | 1013 | 5258 | 0.1926 | -0.5846 |
| SK-BR-3 | SNS-032 | 10 | uM | LJP6 | 2 | H13 | 72 | hr | 2543 | 1038 | 5438 | 0.1909 | -0.5585 |
| SK-BR-3 | SNS-032 | 10 | uM | LJP6 | 3 | H13 | 72 | hr | 2543 | 928 | 5557 | 0.1670 | -0.5910 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 1 | G24 | 72 | hr | 2543 | 1649 | 5258 | 0.3136 | -0.3387 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 2 | G24 | 72 | hr | 2543 | 1387 | 5438 | 0.2551 | -0.4248 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 3 | G24 | 72 | hr | 2543 | 1573 | 5557 | 0.2831 | -0.3470 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 1 | G23 | 72 | hr | 2543 | 1758 | 5258 | 0.3343 | -0.2970 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 2 | G23 | 72 | hr | 2543 | 1582 | 5438 | 0.2909 | -0.3515 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 3 | G23 | 72 | hr | 2543 | 1711 | 5557 | 0.3079 | -0.2964 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 1 | G22 | 72 | hr | 2543 | 1677 | 5258 | 0.3189 | -0.3280 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 2 | G22 | 72 | hr | 2543 | 1653 | 5438 | 0.3040 | -0.3250 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 3 | G22 | 72 | hr | 2543 | 1810 | 5557 | 0.3257 | -0.2604 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 1 | G21 | 72 | hr | 2543 | 1712 | 5258 | 0.3256 | -0.3146 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 2 | G21 | 72 | hr | 2543 | 1724 | 5438 | 0.3170 | -0.2986 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 3 | G21 | 72 | hr | 2543 | 1801 | 5557 | 0.3241 | -0.2637 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 1 | G20 | 72 | hr | 2543 | 1942 | 5258 | 0.3693 | -0.2270 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 2 | G20 | 72 | hr | 2543 | 1997 | 5438 | 0.3672 | -0.1980 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 3 | G20 | 72 | hr | 2543 | 1875 | 5557 | 0.3374 | -0.2369 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 1 | G19 | 72 | hr | 2543 | 1722 | 5258 | 0.3275 | -0.3108 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 2 | G19 | 72 | hr | 2543 | 1806 | 5438 | 0.3321 | -0.2683 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 3 | G19 | 72 | hr | 2543 | 1666 | 5557 | 0.2998 | -0.3129 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 1 | H24 | 72 | hr | 2543 | 5065 | 5258 | 0.9631 | 0.9296 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 2 | H24 | 72 | hr | 2543 | 4467 | 5438 | 0.8214 | 0.6715 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 3 | H24 | 72 | hr | 2543 | 4675 | 5557 | 0.8412 | 0.7157 |
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 1 | H23 | 72 | hr | 2543 | 5189 | 5258 | 0.9867 | 0.9746 |